AB-343

AB-343

AB-343 is our lead oral coronavirus drug candidate that inhibits the main protease (Mpro), a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks. In our pre-clinical research conducted to date, AB-343 has shown robust pan-coronavirus antiviral activity, no reduction in potency against known SARS-CoV-2 variants and Mpro resistant strains, and a favorable drug-drug interaction profile with a PK profile that shows no need for ritonavir boosting. We are conducting IND-enabling studies with AB-343 to prepare for clinical development later this year.

Our hypothesis

To treat COVID-19 and future coronavirus outbreaks, we believe a combination therapy consisting of compounds that inhibit two essential viral proteins, the SARS-CoV-2 nsp5 main protease (Mpro) and nsp12 viral polymerase, will provide the optimal treatment paradigm. We have nominated AB-343 as our lead Mpro candidate and are continuing our research efforts to identify an nsp12 clinical candidate.